Literature DB >> 96466

Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

J D Elsworth, V Glover, G P Reynolds, M Sandler, A J Lees, P Phuapradit, K M Shaw, G M Stern, P Kumar.   

Abstract

After pretreatment with the selective monoamine oxidase B inhibitor, (-)-deprenyl, in doses sufficient for complete inhibition of the platelet enzyme, 4 normal and 6 parkinsoniam volunteers (2 receiving levodopa and 2 levodopa plus carbidopa) suffered no adverse pressor reaction ('cheese effect') after challenge with oral tyramine in amounts considerably greater than those likely to be encountered in a normal diet. Nor did the levodopa-deprenyl combination itself result in a pressor response. Normal human intestinal mucosa was shown predominantly to contain the deprenyl-insensitive A form of the enzyme, which presumably degraded administered tyramine in the deprenyl-treated volunteers; even those receiving the drug for prolonged periods manifested no 'cheese effect', suggesting that the A form remained uninhibited. Intestinal monoamine oxidase A was able to oxidise dopamine, whereas in human platelet or striatum the amine is a monoamine oxidase B substrate. Like tyramine, oral phenylethylamine challenge with amounts greater than those known to be present in a normal diet similarly gave rise to no adverse reaction in (-)-deprenyl-treated subjects; the reasons for this remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 96466     DOI: 10.1007/bf00426954

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  22 in total

1.  Letter: Chocolate, beta-phenethylamine and migraine re-examined.

Authors:  J W Schweitzer; A J Friedhoff; R Schwartz
Journal:  Nature       Date:  1975-09-18       Impact factor: 49.962

2.  Identification and assay of urinary tryptamine: application as an index of monoamine oxidase inhibition in man.

Authors:  A SJOERDSMA; J A OATES; P ZALTZMAN; S UDENFRIEND
Journal:  J Pharmacol Exp Ther       Date:  1959-07       Impact factor: 4.030

Review 3.  Multiple forms of monoamine oxidase: functional significance.

Authors:  M Sandler; M B Youdim
Journal:  Pharmacol Rev       Date:  1972-06       Impact factor: 25.468

4.  Monoamine oxidase: multiple forms and selective inhibitors.

Authors:  M B Youdim; G G Collins; M Sandler
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

5.  Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo.

Authors:  D S Robinson; W Lovenberg; H Keiser; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1968-01       Impact factor: 5.858

6.  Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect.

Authors:  I P Lapin; G F Oxenkrug
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

7.  The determination of urinary phenylacetylglutamine as phenylacetic acid. Studies on its origin in normal subjects and children with cystic fibrosis.

Authors:  J W Seakins
Journal:  Clin Chim Acta       Date:  1971-11       Impact factor: 3.786

Review 8.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

9.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

10.  Transitory decrease in platelet monoamine-oxidase activity during migraine attacks.

Authors:  V Glover; M Sandler; E Grant; F C Rose; D Orton; M Wilkinson; D Stevens
Journal:  Lancet       Date:  1977-02-19       Impact factor: 79.321

View more
  57 in total

1.  Landmark publications in Psychopharmacology: the first 40 years.

Authors:  K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

Review 2.  Selegiline and Parkinson's disease. Protective and symptomatic considerations.

Authors:  L I Golbe; J W Langston; I Shoulson
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  L-deprenyl plus L-phenylalanine in the treatment of depression.

Authors:  W Birkmayer; P Riederer; W Linauer; J Knoll
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

4.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

5.  Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.

Authors:  J P Finberg; M Tenne
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

6.  Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?

Authors:  J J Askenasy; M D Yahr
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

7.  Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.

Authors:  David S Goldstein; Yunden Jinsmaa; Patti Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

8.  The active centers of monoamine oxidase types "A" and "B": binding with (14C)-clorgyline and (14C)-deprenyl.

Authors:  M B Youdim
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

9.  Absence of "cheese effect" during deprenyl therapy: some recent studies.

Authors:  M Sandler; V Glover; A Ashford; G M Stern
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

10.  Recent observations on the clinical pharmacology of (-)deprenyl.

Authors:  G M Stern; A J Lees; M Sandler
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.